Premium
A phase III study comparing the clinical utility of four regimens of 5‐Fluorouracil. A preliminary report
Author(s) -
Ansfield Fred,
Klotz Jerome,
Nealon Thomas,
Ramirez Guillermo,
Minton John,
Hill George,
Wilson William,
Davis Hugh,
Cornell George
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197701)39:1<34::aid-cncr2820390107>3.0.co;2-2
Subject(s) - medicine , rectum , fluorouracil , colorectal cancer , clinical trial , toxicity , oncology , breast cancer , cancer , schedule , surgery , computer science , operating system
A clinical trial involving 462 colon, rectum, and breast cancer patients randomized among four different dosage regimens of 5‐FU (an intravenous loading course, a weekly intravenous schedule, a nontoxic schedule, and an oral schedule) has shown a significantly better response among colon‐rectum cancer patients for the intravenous loading course. In addition, duration of response and time to progression are also significantly better. Overall survival is approaching significance for the colon rectum group (p value .082). In contrast, breast cancer patients show little difference between treatments. Toxicity is somewhat higher for the loading course.